CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 174 enrolled
Drug / intervention
Paclitaxel +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04425018
NCT04425018Phase 2Active
CompareCT.gov

MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer

Dana-Farber Cancer Institute·interventional·Posted Jun 11, 2020·Updated Nov 18, 2025

In Brief

A Phase 2 clinical trial evaluating Paclitaxel, Pertuzumab, and 2 other interventions for Breast Cancer and 3 related conditions. Active but no longer recruiting, targeting 174 participants across 14 sites.

Detailed Summary

The purpose of this study is to determine how well participants with stage II-III HER2-positive breast cancer respond to pre-operative treatment using one of two different combinations of drugs. Drugs and Combinations used: * Paclitaxel, Pertzumab and Margetuximab (Margenza) * Paclitaxel, Pertzumab and Trastuzumab (Herceptin)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, HER2-positive Breast Cancer
CountriesUnited States
CollaboratorsMacroGenics, Translational Breast Cancer Research Consortium

Timeline

Phase 2Active
2021202220232024202520262027
First PostedJun 11, 2020
Enrollment StartJul 13, 2020
Primary CompletionOct 24, 2024
Study CompletionJul 1, 2027
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 6.1 years ago

Interventions

Paclitaxeldrug

Pre-determined dose administered via IV, Day 1,8,15 of each cycle 4 study cycles, or 12 weeks.

Pertuzumabdrug

Pre-determined dose administered via IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

Margetuximabdrug

Pre-determined dose administered by IV - Day 1 of each 21- day cycle 4 study cycles, or 12 weeks.

Trastuzumabdrug

Pre-determined dose administered via IV Day 1 of each 21- day cycle for 4 study cycles, or 12 weeks.